---
provider: perplexity
model: sonar-deep-research
cached: false
start_time: '2025-12-28T10:42:21.231190'
end_time: '2025-12-28T10:44:47.310409'
duration_seconds: 146.08
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: BRCA1
  gene_symbol: BRCA1
  uniprot_accession: P38398
  protein_description: 'RecName: Full=Breast cancer type 1 susceptibility protein;
    EC=2.3.2.27 {ECO:0000269|PubMed:10500182, ECO:0000269|PubMed:12887909, ECO:0000269|PubMed:12890688,
    ECO:0000269|PubMed:16818604, ECO:0000269|PubMed:18056443, ECO:0000269|PubMed:20351172};
    AltName: Full=RING finger protein 53; AltName: Full=RING-type E3 ubiquitin transferase
    BRCA1 {ECO:0000305};'
  gene_info: Name=BRCA1; Synonyms=RNF53;
  organism_full: Homo sapiens (Human).
  protein_family: Not specified in UniProt
  protein_domains: BRCA1. (IPR011364); BRCA1-associated. (IPR031099); BRCA1_serine_dom.
    (IPR025994); BRCT_dom. (IPR001357); BRCT_dom_sf. (IPR036420)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    reasoning_effort: medium
    search_domain_filter: []
    return_citations: true
    temperature: 0.0
citation_count: 58
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P38398
- **Protein Description:** RecName: Full=Breast cancer type 1 susceptibility protein; EC=2.3.2.27 {ECO:0000269|PubMed:10500182, ECO:0000269|PubMed:12887909, ECO:0000269|PubMed:12890688, ECO:0000269|PubMed:16818604, ECO:0000269|PubMed:18056443, ECO:0000269|PubMed:20351172}; AltName: Full=RING finger protein 53; AltName: Full=RING-type E3 ubiquitin transferase BRCA1 {ECO:0000305};
- **Gene Information:** Name=BRCA1; Synonyms=RNF53;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** BRCA1. (IPR011364); BRCA1-associated. (IPR031099); BRCA1_serine_dom. (IPR025994); BRCT_dom. (IPR001357); BRCT_dom_sf. (IPR036420)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "BRCA1" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'BRCA1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **BRCA1** (gene ID: BRCA1, UniProt: P38398) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

<think>
Let me analyze the query carefully. The user is asking for a comprehensive research report on BRCA1 (UniProt P38398), the breast cancer type 1 susceptibility protein in humans.

The query specifically asks for:
1. Gene/protein identification verification
2. Function, biological processes, and localization
3. For enzymes: what reaction is catalyzed and substrate specificity
4. Where the gene product functions (in/outside cell)
5. Signaling or biochemical pathways
6. Evidence from experimental, structural, evolutionary, and bioinformatic analysis

Let me verify this is the correct protein:
- UniProt P38398: BRCA1 - Breast cancer type 1 susceptibility protein ✓
- EC number 2.3.2.27 - This indicates it's an E3 ubiquitin ligase (transferase enzyme)
- Full name: Breast cancer type 1 susceptibility protein ✓
- Organism: Homo sapiens (Human) ✓
- Gene: BRCA1 ✓
- Key domains: BRCA1, BRCA1-associated, BRCA1_serine_dom, BRCT_dom ✓

The search results provided are highly relevant to BRCA1 and cover:
1. DNA repair functions (homologous recombination)
2. E3 ubiquitin ligase activity
3. Protein-protein interactions
4. Cell cycle checkpoint control
5. Transcriptional regulation
6. Phosphorylation and post-translational modifications
7. Nuclear localization and foci formation
8. Metabolic regulation
9. Interactions with BARD1 and other proteins

I have sufficient search results to create a comprehensive 10,000+ word report on BRCA1 function.

Key sections I should cover:
1. Protein structure and domain organization
2. Primary enzymatic function (E3 ubiquitin ligase activity)


3. Role in homologous recombination-mediated DNA double-strand break repair
4. E3 ubiquitin ligase activity and substrates
5. Protein-protein interactions and complex formation
6. Cell cycle checkpoint control
7. Transcriptional regulation functions
8. Chromatin remodeling and nuclear localization
9. Post-translational modifications and phosphorylation
10. Clinical significance and cancer predisposition

Let me structure this as a comprehensive scientific report.
</think>

# The BRCA1 Protein: Structure, Function, and Mechanisms in Genomic Stability Maintenance

The **BRCA1 (Breast Cancer Type 1 Susceptibility) protein** represents one of the most extensively characterized tumor suppressors in human biology, functioning as a multidomain protein that orchestrates the cellular response to DNA damage through its roles as an E3 ubiquitin ligase and DNA repair orchestrator. This comprehensive report synthesizes recent findings on BRCA1's molecular mechanisms, subcellular localization, biochemical functions, and integration into critical cellular pathways including homologous recombination-mediated DNA double-strand break repair, cell cycle checkpoint control, transcriptional regulation, and metabolic sensing. The approximately 1863 amino acid protein (with EC number 2.3.2.27, indicating ubiquitin transferase activity) operates at the intersection of multiple cellular processes that collectively maintain genomic integrity and suppress malignant transformation.

## Structural Organization and Protein Architecture of BRCA1

The BRCA1 protein displays a modular architecture characterized by multiple functional domains that mediate its diverse cellular roles[1][5][6]. At the N-terminal region lies a **RING finger domain** (amino acids 1-100), which contains two zinc finger-like motifs connected through linking C₃HC₄ regions[1][15]. This domain is essential for the formation of a tight heterodimeric complex with BARD1 (BRCA1-associated RING domain protein), through the establishment of an extensive four-helix-bundle dimerization interface[41]. The RING domain mediates the E3 ubiquitin ligase activity of the BRCA1-BARD1 heterodimer, with the interaction surface formed by helices adjacent to the RING motifs rather than by the zinc-coordinated regions themselves[38][41].

The protein contains multiple distinct functional subdomains within its central and C-terminal regions. Between amino acids approximately 1280 and 1524, BRCA1 contains an SQ cluster region with multiple serine residues that serve as targets for phosphorylation by damage-responsive kinases such as ATM and Chk2[37][59]. The C-terminal region of BRCA1 comprises two tandem BRCT (BRCA1 C-terminal) domains connected by a 22-amino-acid linker[23]. Each BRCT repeat consists of three α-helix structures arranged around a four-stranded β-sheet core[23]. These BRCT domains form a head-to-tail structure involving hydrophobic interactions between the α2 helix of BRCT1 and the α1 and α3 helices of BRCT2[23]. The BRCT domains function as phosphoprotein binding modules that recognize the phosphorylated protein sequence motif pSXXF (phosphoserine-X-X-phenylalanine) of various kinase substrates, enabling phospho-dependent protein-protein interactions critical for DNA damage response functions[23][20].

The transactivation domain of BRCA1, comprising the last 570 amino acids including both BRCT repeats, independently confers transcriptional activation capability[43]. This domain includes activation domain 1 and the two BRCT repeats themselves, which act synergistically to stimulate transcription[43]. The minimal transactivation domain identified encompasses exons 21-24 (amino acids 1760-1863), with sequences in adjacent exons 16-20 enhancing full activity[8].

## Primary Enzymatic Function: E3 Ubiquitin Ligase Activity and Substrate Specificity

The biochemical hallmark of BRCA1 function centers on its role as a component of a RING-type E3 ubiquitin ligase complex with BARD1[1][3][6][38][41]. **The E3 ubiquitin ligase activity represents the only directly catalytic enzymatic function with established kinetic parameters**, characterized by EC number 2.3.2.27 (transferase activity)[4]. This activity catalyzes the transfer of ubiquitin molecules from a ubiquitin-conjugating enzyme (E2) to protein substrates, a process essential for ubiquitin-dependent cellular signaling and protein regulation.

NMR spectroscopy studies demonstrate that the ubiquitin-conjugating enzyme UbcH5c binds exclusively to the BRCA1 RING domain, not the BARD1 RING, with the binding interface formed by the first and second zinc-binding motifs of the BRCA1 RING[41]. Single residue changes on the UbcH5c recognition surface of BRCA1 are sufficient to severely decrease or abrogate ubiquitin ligase activity[41]. Notably, BRCA1 and BARD1 RING domains have evolved what appears to be **attenuated catalytic activity** compared to other RING-containing proteins[38]. The BARD1 RING domain itself appears to play an attenuating role on BRCA1 ligase activity; disruption of the BARD1 RING through zinc-coordinating ligand mutations unexpectedly increases BRCA1 ligase activity, while complete elimination of the BARD1 RING still supports BRCA1 ligase activity as long as the BRCA1-binding helices remain[38].

**In vivo substrate specificity** for the BRCA1-BARD1 complex has remained partially enigmatic despite decades of research, though several substrates have been characterized. Histone H2A and the phosphorylated histone variant H2AX (γ-H2AX) represent well-characterized BRCA1-BARD1 substrates[13][16]. Following DNA damage, BRCA1 forms acid-stable biochemical complexes with γ-H2AX on chromatin and catalyzes ubiquitination at lysine residues 118 and 119 of H2AX[13]. This ubiquitination is proteasome-dependent, and when BRCA1 levels are reduced, H2AX ubiquitination is substantially reduced while phosphorylated H2AX levels increase, suggesting BRCA1 participates in attenuating the γ-H2AX repair signal as a late phase of DNA repair[13]. Additional histone substrates include H2B, H3, and H4, though H1 is notably not ubiquitinated by BRCA1-BARD1[16].

Recent comprehensive studies using full-length BRCA1-BARD1 have established robust, substrate-specific ubiquitylation activity with previously unrecognized modes of activity modulation[3]. The investigation revealed that BRCA1-BARD1 ligase activity is required not only for DNA resection during homology-directed repair but also for **later stages of HDR completion**, suggesting substrates critical to strand exchange and D-loop formation remain to be fully characterized[3]. Separation-of-function alleles that are truly ligase-null or specifically impaired in nucleosomal histone targeting render cells hypersensitive to DNA-damaging agents, establishing that ubiquitin E3 activity contributes to multiple sequential stages of DNA repair rather than a single discrete step[3].

## The BRCA1-BARD1 E3 Ubiquitin Ligase Complex and Nuclear Trafficking

The assembly and localization of the BRCA1-BARD1 complex represents a crucial regulatory mechanism for BRCA1 function[7][10]. BARD1 functions as a critical nuclear chaperone for BRCA1; BARD1 directly masks the BRCA1 nuclear export signal and mediates RING-dependent BRCA1 nuclear import through complex formation[7]. Both components of this BRCA1 RING-domain mediated interaction are required for nuclear localization of ectopic and endogenous BRCA1[7]. Notably, BRCA1 exon 11 splice variants, which lack the previously identified nuclear localization signals (NLSs) but retain the RING domain, are frequently detected in the nucleus and in nuclear foci in vivo, explaining this apparent paradox through BARD1-mediated nuclear targeting[7].

The subcellular distribution of BARD1 undergoes cell cycle-dependent changes that reflect its functional association with BRCA1[10]. While BRCA1 expression and nuclear accumulation increase dramatically in S-phase cells, BARD1 levels remain relatively constant throughout the cell cycle; however, BARD1 specifically localizes within BRCA1 nuclear dots during S-phase but not during G₁ phase[10]. This cell cycle-dependent colocalization indicates a role for BARD1 in BRCA1-mediated tumor suppression that is particularly active during DNA replication. Co-expression of BARD1 promotes formation of DNA damage-induced nuclear foci containing wild-type or NLS-deficient BRCA1, further implicating BARD1 in nuclear targeting of BRCA1 for DNA repair functions[7]. These results reveal that BARD1's effects on BRCA1 protein stability, ubiquitin ligase activity, and DNA repair function are mediated in part through its role as a BRCA1 nuclear chaperone[7].

## BRCA1 and Homologous Recombination-Mediated DNA Double-Strand Break Repair

The role of BRCA1 in homologous recombination (HR) mediated repair represents the primary mechanism contributing to its tumor suppression activity[2][5]. **HR is required for repairing multiple types of DNA damage including single-stranded DNA lesions, DNA double-strand breaks (DSBs), and DNA cross-links**[2]. Additionally, HR is a critical mechanism for recovery of stalled or broken DNA replication forks, with certain genetic alterations such as BRCA1 mutations conferring increased risk of malignancy and enhanced sensitivity to chemotherapeutic agents, including PARP inhibitors[2][5]. The observation that BRCA1 associates and colocalizes with RAD51 in nuclear foci in mitotic cells represents one of the earliest indications that BRCA1 functions in HR repair[2]. These foci form before and after DNA damage, indicating BRCA1's role in both repair of intrinsic and induced DNA damage[2].

BRCA1 functions in HR repair through two major mechanistic steps: **(1) promotion of 5′ to 3′ end resection of DSBs to generate 3′ single-stranded DNA (ssDNA) overhangs**, and **(2) loading of the RAD51 recombinase onto the ssDNA**[5][14][17]. End resection represents a key decision point in DSB repair pathway selection, as it promotes pathways utilizing homology (HR and single-strand annealing) while suppressing canonical non-homologous end joining (NHEJ)[5]. BRCA1 involvement in resection was first suggested by observations that BRCA1 mutant cells are defective in single-strand annealing (SSA), a homology-based DSB repair pathway that relies on a resection intermediate[5]. Consistent with a resection role, BRCA1 colocalizes with the resection complex MRE11-RAD50-NBS1 (MRN) after DNA damage and directly interacts with the resection factor CtIP (C-terminal binding protein-interacting protein)[5].

The detailed mechanisms of BRCA1-dependent end resection have been elucidated through studies of replication fork stalling and collapse[2]. Following replication fork collapse or stalling induced by DNA-damaging agents, BRCA1 promotes repair through distinct mechanisms. The observation that BRCA1 associates and colocalizes with RAD51 at ssDNA regions following hydroxyurea (HU) treatment even in the absence of detectable DSBs indicates BRCA1's involvement in HR upon replication fork stalling[2]. When BRCA1 is depleted, reduced proportions of cells with RAD51 foci and sister chromatid exchange (SCE) frequency are observed under replication stress conditions without DSBs, suggesting BRCA1 regulates RAD51 recruitment in the absence of DNA DSBs[2]. This study was the first to illuminate how BRCA1 deficiency influences HR repair in the context of stalled replication forks[2].

BRCA1 promotes repair of DSBs following replication fork collapse via multiple mechanisms, whereas **BRCA1 promotes HR following replication fork stalling solely via facilitation of ssDNA resection**[2]. The interaction between CtIP and BRCA1 appears central to resection regulation; cells expressing CtIP protein that cannot be phosphorylated at serine 327 are specifically defective in HR with decreased ssDNA levels following X-ray damage[2]. This supports a model in which phosphorylation of CtIP S327 as cells enter S-phase and recruitment of BRCA1 function as a molecular switch shifting DSB repair balance from error-prone end-joining to error-free HR by facilitating ssDNA resection[2]. Furthermore, knockdown or loss of BRCA1 protein results in increased frequency of plasmid DNA mutagenesis and microhomology-mediated end joining following DSBs, suggesting BRCA1 protects DNA from mutagenesis during non-homologous DSB repair[2].

### BRCA1 as an Antagonist of 53BP1 and Regulation of Repair Pathway Choice

BRCA1 functions as an antagonist of 53BP1 (tumor suppressor p53-binding protein 1), which serves as a resection suppressor[5]. In the absence of BRCA1, 53BP1 accumulates at DSBs to block resection and HR, ultimately leading to chromosomal aberrations and cell death; deletion of 53BP1, however, rescues the viability of BRCA1 mutant cells and mice, as well as HR defects of BRCA1-deficient cells[5]. This antagonism extends beyond DSB repair; 53BP1 and BRCA1 have antagonistic interactions governing fork restart pathways, with 53BP1 promoting a fork cleavage-free pathway while BRCA1 facilitates a break-induced replication (BIR) pathway coupled with SLX-MUS complex-mediated fork cleavage[25][28]. The antagonistic functions of 53BP1 and BRCA1 in replication restart mimic their counteracting functions in DSB repair, with both processes involving mutually counteracting functions at initiation steps[25].

### BRCA1 as a Recombination Mediator and Facilitator of RAD51 Loading

While BRCA2 is directly involved in RAD51-mediated repair, BRCA1 acts through more complicated mechanisms via interaction with other proteins[2]. The BRCA1-PALB2-BRCA2 axis plays essential roles in the cellular response to DSBs, maintenance of genome integrity, and suppression of cancer development[17]. Upon DNA damage, BRCA1 is recruited to DSBs where it facilitates end resection and recruits PALB2 and its associated BRCA2 to load RAD51 to initiate HR repair[17]. In the HR pathway, BRCA1 functions upstream of BRCA2, facilitating DSB end resection while BRCA2 loads RAD51 to resected ssDNA to initiate strand invasion[17].

The direct interaction between BRCA1 and PALB2 represents the primary mechanism for PALB2, BRCA2, and RAD51 recruitment to DSBs in normal cells[17]. BRCA1 associates with BRCA2 through PALB2/FANCN, with PALB2 serving as the linker between BRCA1 and BRCA2[14]. BRCA1 is an upstream regulator of BRCA2 in the DNA-damage response, with PALB2 being the direct linker[14]. The interaction between PALB2 and BRCA1 occurs constitutively and is DNA-damage-independent, comparable to the interaction between PALB2 and BRCA2[14]. In PALB2-null cells, BRCA2 fails to co-immunoprecipitate with BRCA1, whereas reconstitution with wild-type PALB2 restores the association between BRCA1 and BRCA2[14].

BRCA1 is required for targeting PALB2 and BRCA2 to DNA-damage sites[14]. In the presence of intact BRCA1, its direct interaction with PALB2 plays a dominant role for targeting PALB2-BRCA2-RAD51 to DSB-proximal chromatin, with the interaction between RNF168 and PALB2 helping retain the recruited PALB2[17]. The BRCA1 coiled-coil motif interacts with the N-terminal coiled-coil motif of PALB2, and deletions of conserved residues within these motifs abrogate the binding[14]. The interaction between BRCA1 and PALB2 is critical for HR repair, cell cycle checkpoint control, genome stability, and tumor suppression[17]. In absence of BRCA1 or in cells with mutations disrupting BRCA1-PALB2 interaction, PALB2 can be recruited through backup mechanisms involving RNF168 and other pathways to sustain residual HR[17].

Recent structural and functional studies have comprehensively mapped BRCA1-BRCT domain interactions with HR regulatory proteins[20]. The tandem BRCT domains mediate phospho-dependent interactions with multiple proteins including ABRAXAS1, CtIP, and BRIP1, with a common phosphorylated motif in these three proteins competing for a shared binding pocket within the BRCT domains[20]. Many pathogenic missense mutations cluster within this pocket and are known to impair HR; for instance, mutations at arginine 1699, such as R1699W, result in HR deficiency and are clinically recognized as pathogenic[20]. Site-saturated mutagenesis of the BRCT domains generated over 4,000 mutants assessed for binding to ABRAXAS1 and CtIP, enabling construction of an extensive interaction landscape[20]. Loss of CtIP binding resulted in the most pronounced impact on HR, indicating differential functional importance of specific BRCT-mediated interactions[20].

## Post-translational Modifications and Phosphorylation-Dependent Functions

BRCA1 undergoes dynamic phosphorylation at multiple sites in response to DNA damage, with these modifications regulating distinct cellular functions[37][59]. Upon DNA damage induced by ionizing radiation, BRCA1 protein is rapidly phosphorylated by multiple kinases involved in DNA repair and cell-cycle checkpoint control including ATM, CHK2, and ATR[37]. **ATM-dependent phosphorylation occurs at multiple serine residues**; however, the specific ATM phosphorylation sites mapped in vivo and in vitro are not completely identical[37].

The ATM phosphorylation site at mouse BRCA1-S1152 (corresponding to human BRCA1-S1189) appears functionally critical[37]. Mutation of mouse BRCA1-S1152 resulted in increased genomic instability and tumor incidence, indicating this site is functionally important for DDR and DSB repair[37]. BRCA1-S1152 is part of a feedback loop that sustains ATM activity; abrogation of phosphorylation at this site impairs end resection without affecting assembly of the MRE11-RAD50-CtIP resection complex at DSBs[37]. Consistently, both Brca1^S971A/S971A^ MEFs (disrupting Chk2 phosphorylation) and Brca1^S1152A/S1152A^ MEFs showed impaired end resection[37]. Most remarkably, ATM phosphorylation upon γ-irradiation was significantly impaired in Brca1^S1152A/S1152A^ cells, and the "SKP2-NBS1 ubiquitination-ATM activation" circuit is impaired in these cells, indicating BRCA1-S1152 phosphorylation sustains ATM activation in a feedback mechanism[37].

The Chk2-mediated phosphorylation at BRCA1-S988 regulates both promotion of HR and suppression of error-prone NHEJ[56]. Prevention of Chk2-mediated phosphorylation via mutation of serine 988 disrupted both BRCA1-dependent promotion of HR and suppression of NHEJ; similar results were obtained when endogenous Chk2 kinase activity was inhibited[56]. Intriguingly, the opposing regulation of HR and NHEJ did not require ATM phosphorylation sites on serines 1423 and 1524[56], suggesting dual regulatory roles for distinct BRCA1 phosphorylation events[56]. This dual regulation indicates a functional link between recombination control and breast cancer predisposition in carriers of Chk2 and BRCA1 germ-line mutations[56].

ATM-dependent phosphorylation at BRCA1-S1387 is specifically required for ionizing radiation-induced S-phase arrest but not G₂-M checkpoint control[59]. Overexpression of a BRCA1 protein with serine 1387 mutated to alanine specifically abrogates the IR-induced S-phase arrest, acting as a dominant-negative activity[59]. In contrast, phosphorylation at BRCA1-S1423 is important for IR-induced G₂-M checkpoint arrest but not the S-phase checkpoint, demonstrating that distinct BRCA1 phosphorylation sites mediate distinct functional roles[59]. Among multiple serine sites, ionizing irradiation appears to induce phosphorylation of serines 1387, 1423, and 1524 in an ATM-dependent manner[59].

BRCA1 also undergoes ATR-dependent phosphorylation at serine-1423 in response to replication stress, distinct from ATM-mediated phosphorylation[50]. Following DNA damage, phosphorylated BRCA1 (BRCA1^pSer-1423^) recruits BCLAF1 and associated spliceosomal proteins, facilitating DNA damage-induced mRNA splicing[50]. This phosphorylation event represents a commitment step in BRCA1-dependent functions following DNA damage, activating formation of the BRCA1-mRNA splicing complex[50].

## Cell Cycle Checkpoint Control Functions of BRCA1

BRCA1 plays critical roles in controlling cell cycle checkpoints at multiple phases, particularly the G₁/S and G₂/M transitions in response to DNA damage[12][31]. The ATM-BRCA1/BARD1-p53-p21 axis represents a major checkpoint regulatory mechanism; phosphorylation of human ATM-S1981 (mouse ATM-S1987) has been well-established as a marker of ATM kinase activation[37]. BRCA1-BARD1 mediates acute suppression that compromises p53(Ser-15) phosphorylation, which in turn compromises p21 induction and G₁/S checkpoint arrest[12]. These observations reveal an important role of p21 in mediating BRCA1 function in G₁/S arrest, with p21 induction transcription requiring p53 activation[12].

BRCA1 functions as a co-activator of p53-dependent transcription, but with remarkable selectivity[9]. BRCA1-stabilized p53 regulates transcription of DNA repair and growth arrest genes while p53 stabilized by DNA-damaging agents induces a broader array of genes including those involved in apoptosis[9]. The differential expression profile results in growth arrest following BRCA1 expression versus apoptosis following DNA damage, indicating BRCA1 exerts selective control over p53 transcriptional targets[9]. Depletion of BRCA1 in wild-type-p53-expressing cells abolishes induction of repair genes such as p53R2, while expression of PIG3 (an apoptosis-inducing gene) is still induced[9]. BRCA1 also confers diminished cell death in a p53-dependent manner in response to adriamycin compared to controls[9].

The molecular mechanism appears to involve BRCA1 associating with and stabilizing p53 alongside other stabilizing events such as phosphorylation, and directing p53 transcription towards growth arrest and DNA repair genes[9]. After DNA damage, BRCA1 associates with and stabilizes p53, directing p53 transcription towards growth arrest and DNA repair genes, allowing growth arrest and repair to proceed[9]. If damage to the genome is significant and repair continues for extended periods, p53 overcomes the BRCA1-mediated effect through repression of the BRCA1 gene and proceeds to activate the apoptosis pathway[9]. This temporal control mechanism allows cells time for DNA repair before committing to programmed cell death.

Evidence indicates that BRCA1 deficiency activates the ATM-Chk2-p53 DNA damage response pathway as a natural barrier against malignant transformation[12][31]. BRCA1^Δ11/Δ11^ cells die early in utero, but this lethality can be partially rescued by a nullizygous p53 mutation[1]. Deletion of p53 and/or its downstream mediator p21 partially rescues BRCA1-null embryos, with elimination of either one or both wild-type p53 alleles completely overcoming embryonic lethality caused by targeted deletion of full-length Brca1[31]. Haploid loss or complete loss of ATM also rescued Brca1 deficiency-associated embryonic lethality and premature aging[31]. ATM or Chk2 inactivation is equivalent to p53 inactivation in allowing Brca1^Δ11/+^ embryos to survive to adulthood[31]. These genetic interactions demonstrate that the activation of the ATM-Chk2-p53 signaling pathway in response to Brca1 deficiency contributes to suppression of neoplastic transformation while compromising organismal homeostasis[31].

## BRCA1 Localization and Nuclear Foci Formation

BRCA1 demonstrates dynamic subcellular localization patterns that reflect its functional roles in nuclear processes[21][24]. BRCA1 forms approximately 10-20 prominent nuclear foci in normal cells, with these foci localizing predominantly to heterochromatic nuclear regions[24]. BRCA1 frequently associates with interphase centromere-kinetochore complexes, including pericentric heterochromatin, particularly the nucleolar periphery where many centromeres reside[21][24]. Approximately 32% of BRCA1 foci localize to the region abutting or within the nucleolus, another 14% localize to peripheral heterochromatin, and 35% colocalize with small discrete "holes" in hnRNA signal[24]. This heterochromatin-associated localization suggests BRCA1 involvement in replication-linked maintenance of centric/pericentric heterochromatin[21][24].

BRCA1 demonstrates S-phase-dependent accumulation into nuclear foci with spatially discrete organization[10][21]. Most BRCA1 foci position overwhelmingly in heterochromatic regions; BRCA1 does not substantially colocalize with facultative heterochromatin markers like H3mK27 or XIST RNA on the inactive X chromosome[24]. Through simultaneous detection of nuclear RNA and protein using optimized methods, BRCA1 partially overlaps or closely abuts XIST RNA in only 3-5% of cells, with 3D analysis showing even apparent overlaps are largely distinct spatial territories[24]. Proliferating cell nuclear antigen or BrdU labeling demonstrates BRCA1 localizes adjacent to or "paints" major satellite blocks as chromocenters replicate, where topoisomerase is also enriched[21][24].

The mechanism underlying BRCA1 accumulation into nuclear dots and its S-phase-dependent organization remains incompletely understood, although **BRCA1 undergoes hyperphosphorylation at S-phase**, which may be significant[10]. BRCA1 loss is often associated with proliferative defects including postmitotic bridges enriched with satellite DNA, suggesting a novel mechanism whereby BRCA1 loss contributes to genomic instability[21]. These findings implicate BRCA1 in replication-linked maintenance of centric/pericentric heterochromatin as a previously unrecognized function distinct from damage-induced foci formation[21][24].

## Transcriptional Regulation Functions and Target Gene Selection

BRCA1 functions as a transcriptional regulator with selectivity for specific target genes, involving both transcriptional activation and repression mechanisms[8][9][27][32]. The C-terminal region of BRCA1, comprising exons 16-24 (amino acids 1560-1863), can activate transcription when fused to a heterologous GAL4 DNA binding domain both in yeast and mammalian cells[8]. The minimal transactivation domain comprises exons 21-24 (amino acids 1760-1863), with exons 16-20 contributing to full activity[8]. The presence of an acidic region, nuclear localization signals, and zinc finger domain in BRCA1 suggests a role in transcriptional regulation[8].

Germ-line mutations in BRCA1 impair transcriptional activation; four reported mutations associated with disease (Ala-1708→Glu, Gln-1756 C+, Met-1775→Arg, Tyr-1853→Stop) demonstrated markedly impaired transcription activity[8]. Most mutations found in patients generate proteins lacking all or part of the minimal transactivation domain; for instance, truncated proteins lacking even small regions of this domain would be predicted to have no function in transcriptional activation[8]. This suggests that mutations in BRCA1 impairing the ability to activate transcription may predispose carriers to tumors, indicating BRCA1 may function to activate transcription of genes involved in suppressing transformation[8].

BRCA1 participates in regulating **insulin-like growth factor 1 receptor (IGF1R)** gene expression through interaction with the zinc-finger transcription factor Sp1[19]. The mechanism involves BRCA1 binding to and sequestering Sp1, preventing Sp1 from binding cis-elements in the IGF1R promoter region, leading to reduction in IGF1R levels and ensuing decrease in IGF1-mediated proliferation[19]. Loss-of-function BRCA1 mutations render mutant BRCA1 unable to bind Sp1 and suppress IGF1R gene transcription, with enhanced IGF1R levels associated with augmented cell proliferation[19]. Maximal BRCA1 expression occurs during the pre-replicative G₁ phase of the cell cycle, and BRCA1 is involved in control of G₁-S and G₂-M transition checkpoints[19].

BRCA1 associates with regulatory regions of genes involved in DNA repair and checkpoint control, including the rRNA genes regulated by RNA Polymerase I (Pol-I)[32]. BRCA1 associates with the rDNA repeat and interacts with components of Pol-I transcription machinery including the upstream binding factor (UBF) and selectivity factor-1 (SL1), as well as RNA Pol-I itself[32]. A rDNA-associated fraction of BRCA1 is involved in DNA damage-dependent regulation of Pol-I transcription, regulating the stability and formation of the Pol-I holoenzyme during initiation and/or elongation in response to DNA damage[32]. BRCA1 occupancy at the rDNA repeat is decreased in response to DNA damage, and the observed BRCA1 interactions with Pol-I transcription machinery are weakened[32]. These findings indicate BRCA1 has novel regulatory functions in the control of Pol-I transcription and therefore ribosome biogenesis[32].

## Metabolic Sensing and Regulation of BRCA1 Expression

BRCA1 expression undergoes dynamic regulation in response to cellular metabolic status through a "metabolic switch" mechanism involving the C-terminal-binding protein (CtBP) and histone deacetylase 1[22][29]. **Estrogen represents the most potent stimulus for BRCA1 expression**, inducing 6-7-fold increases in both mature and unspliced (nascent) BRCA1 RNA in hormone-responsive cells[29]. This regulation reflects a direct link between cellular metabolic status and the expression of BRCA1, suggesting caloric intake may selectively influence the levels of tumor suppressor function in mammary tissues[22].

BRCA1 transcription is controlled by a dynamic equilibrium between transcriptional co-activators and co-repressors that govern histone modifications at the BRCA1 promoter[22]. CtBP assembles at the BRCA1 promoter as part of a multi-component co-repressor complex containing p130, HDAC1, and other factors that represses local histone acetylation and BRCA1 transcription[22]. Eviction of CtBP from the BRCA1 promoter through estrogen induction, RNAi depletion, or increased NAD⁺/NADH ratio results in HDAC1 dismissal, elevated histone acetylation, and increased BRCA1 transcription[22]. This represents an important molecular link between caloric intake and tumor suppressor expression in mammary cells[22].

CtBP functions as a "metabolic switch" at the BRCA1 promoter selectively controlling histone acetylation, chromatin structure, and transcription in response to cellular metabolic status[22]. CtBP is most active as a dimer with dimerization promoted by binding to NAD⁺ and NADH[22]. CtBP has greater than 100-fold higher affinity for NADH compared to NAD⁺, and free cellular concentrations of both NAD species approach their CtBP binding affinities[22]. Hypoxia produces a selective block to estrogen induction of BRCA1 transcription while not influencing induction of other estrogen-responsive genes, demonstrating CtBP functions as a metabolic switch controlling BRCA1 expression specifically[22].

BRCA1 induces metabolic reprogramming in breast cancer cells as demonstrated by global metabolomics and transcriptomics platforms[19]. Wild-type BRCA1 induces numerous metabolic modifications including marked inhibition of glycolysis; all glycolysis indicators were largely decreased (~50%) in BRCA1 wild-type compared to BRCA1 mutant cells[19]. Five major glycolytic enzymes including HK2 and PFKFB3, and both pyruvate and lactate were down-regulated by BRCA1 transfection[19]. Conversely, the tricarboxylic acid (TCA) cycle and oxidative phosphorylation were activated in BRCA1-expressing cells[19]. BRCA1 induced a decrease of ketone bodies and free fatty acids, which were likely employed to supply Acetyl-CoA for the TCA cycle[19]. BRCA1-transfected cells displayed enhanced activity of antioxidative pathways, likely as a result of ROS production by oxidative phosphorylation[19]. The overall implication is that BRCA1 is capable of reversing the Warburg effect[19].

## RNA Processing and mRNA Splicing Functions

BRCA1 participates in regulating pre-mRNA splicing of numerous genes involved in DNA damage signaling and repair through formation of a DNA damage-induced BRCA1-mRNA splicing complex[50][57]. This complex contains BCLAF1 (BCL2-associated factor 1) and other key components of the mRNA-splicing machinery[50]. In response to DNA damage from multiple sources (MMS-induced DNA alkylation, HU-induced replication fork stalling, and DSBs from IR and etoposide), BCLAF1 interacts with BRCA1, mediated through phosphorylation of BRCA1 at serine-1423[50]. This complex formation appears as part of a general DNA damage response mechanism, reflecting BRCA1^Ser-1423^ being a substrate of both ATM (in response to DSBs) and ATR (in response to single-strand breaks and stalled forks)[50].

BRCA1, constitutively bound at gene promoters, regulates expression following DNA damage through recruitment of BCLAF1 and the cotranscriptional spliceosome, promoting mRNA splicing and transcript production/stability[50]. Phosphorylated BRCA1 bound at promoters facilitates DNA damage-induced mRNA splicing through recruitment of spliceosomal proteins; mRNA splicing of ATRIP, BACH1, and EXO1 transcripts was significantly upregulated in response to DNA damage in both BRCA1- and BCLAF1-dependent manner[50]. This regulation operates through the nonsense-mediated decay (NMD) pathway; siRNA-mediated depletion of SMG1, a key NMD pathway player, led to marked increase in pre-spliced ATRIP, BACH1, and EXO1 mRNAs in BRCA1- and BCLAF1-depleted cells following DNA damage[50]. These observations define a direct link between phosphorylation-dependent BRCA1 function and the control of DNA damage response gene expression[50].

The THRAP3 and BCLAF1 factors promote selective mRNA splicing and export of transcripts encoding key DNA damage response proteins including the ATM kinase[57]. THRAP3 contains a serine-arginine (SR) rich region consistent with a role in pre-mRNA processing and splicing[50]. THRAP3 is phosphorylated at five different serine residues in an ATR kinase-dependent manner in response to DNA-damaging agents, and is PARylated in response to oxidative stress, which facilitates its localization to nuclear speckles with other splicing factors[57]. Loss of THRAP3 and/or BCLAF1 leads to sensitivity to DNA-damaging agents, defective DNA repair, and genomic instability[57].

## Protection Against Oxidative DNA Damage

BRCA1 and BRCA2 are essential for the repair of oxidative DNA damage repair intermediates that persist into S-phase, producing double-strand breaks[33]. Hydrogen peroxide exposure leads to oxidative DNA damage-induced DSBs in BRCA-deficient cells, causing them to accumulate in S-phase[33]. After hydrogen peroxide treatment, BRCA-deficient cells showed impaired RAD51 foci formation, which is dependent on an intact BRCA1-BRCA2 pathway[33]. These DSBs result in increased chromatid-type aberrations characteristic for BRCA1 and BRCA2-deficient cells[33]. The most common result of oxidative DNA damage-induced processing of S-phase DSBs is an interstitial chromatid deletion, though insertions and exchanges are also observed in BRCA-deficient cells[33].

The implication is that DSBs formed in S-phase cells cannot be processed by the HR machinery when BRCA1 or BRCA2 are deficient[33]. Illegitimate end-joining results as a consequence of failure to process DSBs in the normal time frame, producing the characteristic chromatid-type aberrations[33]. These observations suggest HR is utilized in repair of oxidative DNA damage-produced DSBs arising in S-phase, and that oxidative stress plays a role in the etiology of hereditary breast cancer[33]. The tissue specificity of breast and ovarian cancer in BRCA mutation carriers may relate in part to the oxidative metabolic profile of these tissues[33].

## Chromatin Remodeling and Large-Scale Chromatin Decondensation

Targeting BRCA1 to an amplified lac operator-containing chromosome region in the mammalian genome results in large-scale chromatin decondensation, a function independently conferred by three subdomains within the transactivation domain of BRCA1: activation domain 1 and the two BRCT repeats[43]. This chromatin unfolding activity is not accompanied by histone hyperacetylation, distinguishing it from other well-characterized transactivation domains such as VP16, E2F1, and p53, which all induce chromatin unfolding accompanied by histone hyperacetylation[43].

Deletion analysis showed that chromatin-unfolding activity is conferred by the last 570 amino acids of BRCA1, while further dissection revealed that the 50-amino-acid C-terminal half of BRCT1 is sufficient for inducing maximal chromatin unfolding[43]. The N-terminal half of BRCT1, despite comparable size, fails to mediate any chromatin decondensation, suggesting specific structural elements within BRCT1C confer this activity[43]. Cancer-predisposing mutations of BRCA1 display allele-specific effects on chromatin unfolding: 5′ mutations resulting in gross truncation abolish chromatin unfolding activity, whereas 3′ region mutations markedly enhance this activity[43].

A novel BRCA1 cofactor designated COBRA1 is recruited to chromosome sites by the first BRCT repeat of BRCA1 and is itself sufficient to induce chromatin unfolding[43]. BRCA1 mutations that enhance chromatin unfolding also increase BRCA1's affinity for and recruitment of COBRA1[43]. These results indicate that reorganization of higher-order chromatin structure is an important regulated step in BRCA1-mediated nuclear functions[43]. BRCA1 recruitment of nucleases might generate products unsuitable for 53BP1 and RIF1 binding, or BRCA1 might destabilize the chromatin structures necessary for 53BP1 and RIF1 accumulation[25].

## Protein-Protein Interaction Networks and Multiprotein Complex Assembly

BRCA1 binds to numerous cellular proteins that together coordinate its diverse functions in DNA repair, transcriptional activation, and cell cycle control[1][5]. These proteins likely mediate BRCA1's involvement in DNA repair, transcriptional transactivation, and cell cycle control[1]. Wild-type BRCA1 protein binds DNA repair protein RAD51, tumor suppressor p53, RNA polymerase II holoenzyme, RNA helicase A, CtBP-interacting protein, c-myc, BARD1, BRCA2 protein, and numerous other factors[1].

The BRCA1-ABRAXAS-RAP80 complex represents a key BRCA1-associated complex mediating DNA damage recognition and BRCA1 recruitment[49]. Phosphopeptide affinity proteomic analysis identified ABRAXAS protein binding the BRCA1 BRCT repeats through a phospho-Ser-X-X-Phe motif[49]. ABRAXAS binds BRCA1 to the mutual exclusion of BACH1 and CtIP, forming a distinct type of BRCA1 complex[49]. ABRAXAS recruits the ubiquitin-interacting motif (UIM)-containing protein RAP80 to BRCA1; both ABRAXAS and RAP80 were required for DNA damage resistance, G₂-M checkpoint control, and DNA repair[49]. RAP80 was required for optimal accumulation of BRCA1 on damaged DNA (foci) in response to ionizing radiation, and the UIM domains alone were capable of foci formation[49]. The RAP80-ABRAXAS complex may help recruit BRCA1 to DNA damage sites in part through recognition of ubiquitinated proteins[49].

BRCA1 also directly interacts with Fanconi anemia proteins, directly connecting BRCA1 to the FA pathway of DNA repair[51]. This connection indicates BRCA1 participates in interstrand crosslink (ICL) repair and other FA pathway functions beyond its established roles in homologous recombination[51]. The Fanconi anemia pathway involves monoubiquitination of FANCI and FANCD2 proteins by the FA core complex, with downstream participation of BRCA1 (designated FANCS) in HR during ICL repair[54]. BRCA1 and other HR proteins work at earlier steps of ICL repair to protect DNA at the ICL from inappropriate degradation by the DNA2 nuclease-WRN complex[54].

BRCA1 interacts with the basal Pol-II transcription factors and components of the mRNA splicing machinery through multiple interaction surfaces[35][50]. Two RNA polymerase II subunits, hRPB2 and hRPB10α, mediate regulated stimulation of transcription by BRCA1[35]. This broad interaction network enables BRCA1 to function as a cellular hub coordinating diverse DNA damage response processes.

## Hereditary Breast and Ovarian Cancer Susceptibility

Mutations in BRCA1 account for a substantial proportion of hereditary breast and ovarian cancer cases, with approximately half of familial breast cancer cases bearing mutations in BRCA1[1][44]. The majority of BRCA1 mutations produce a truncated protein, and BRCA1-associated breast tumors exhibit defined tumor phenotypes[1]. BRCA1-related breast cancers are more likely than sporadic breast cancers to be triple-negative (lacking estrogen receptors, progesterone receptors, and HER2/neu protein), making them harder to treat with poorer prognosis[47].

People who inherit a harmful change in BRCA1 have markedly increased risks of several cancers, most notably breast and ovarian cancer but also several other cancer types[47]. **More than 60% of women who inherit a harmful change in BRCA1 will develop breast cancer during their lifetime**, compared with approximately 13% of women in the general population[47]. **About 39-58% of women who inherit a harmful change in BRCA1 will develop ovarian cancer during their lifetime**, compared with about 1.1% in the general population[47]. Additionally, mutations in BRCA1 are associated with approximately 5% lifetime risk of pancreatic cancer and increased risks of prostate, skin, stomach, and gallbladder cancers[47].

Among women diagnosed with breast cancer, those with an inherited harmful change in BRCA1 have an increased risk of developing cancer in the opposite (contralateral) breast in the future compared with those without such changes[47]. Approximately 30-40% of breast cancer survivors with inherited BRCA1 changes will develop contralateral breast cancer by 20 years after their first diagnosis, compared with about 8% in the general population[47].

## Conclusion and Integration of BRCA1 Functions

BRCA1 emerges from contemporary research as a multi-functional tumor suppressor orchestrating genomic stability through integrated mechanisms spanning DNA damage recognition and repair, transcriptional regulation, cell cycle control, metabolic sensing, and chromatin remodeling[1][2][3][5][9][14][17][20][22][37]. The protein functions as the obligate heterodimeric partner of BARD1 in executing its primary catalytic activity as an E3 ubiquitin ligase (EC 2.3.2.27), targeting substrates including phosphorylated histone H2AX and other chromatin-associated proteins[3][13][38][41]. This enzymatic activity participates in multiple sequential stages of DNA repair from initial DSB resection through later stages of strand exchange and recombination intermediate resolution[3].

The remarkable complexity of BRCA1 biology reflects its centrality in maintaining genomic integrity through parallel and sequential mechanisms. BRCA1 orchestrates homologous recombination-mediated repair through facilitation of DNA end resection, antagonism of 53BP1-mediated NHEJ promotion, and recruitment of PALB2-BRCA2-RAD51 complexes to resected ssDNA[5][14][17]. Simultaneously, BRCA1 governs cell cycle checkpoints through selective activation of p53-dependent transcription favoring DNA repair over apoptosis[9], and regulates expression of repair genes through control of pre-mRNA splicing[50]. The dynamic phosphorylation of BRCA1 at multiple serine residues by ATM, Chk2, and ATR kinases enables integration of multiple DNA damage signals and temporal coordination of distinct repair and checkpoint functions[37][56][59].

BRCA1 localization undergoes dynamic regulation reflecting its functional diversity, with constitutive nuclear localization dependent on BARD1-mediated masking of nuclear export signals[7], concentration into S-phase-dependent nuclear foci[10], and association with heterochromatic regions including centromeres and pericentromeric regions[21][24]. The protein's role in metabolic sensing through CtBP-dependent transcriptional regulation links cellular nutrient and energy status to tumor suppressor expression, providing a mechanistic explanation for how caloric intake and metabolic state influence cancer risk in tissues expressing high BRCA1 levels[22][29].

The substrate specificity of BRCA1 remains partially incompletely characterized despite decades of research, with well-established histone substrates but likely numerous unidentified physiological substrates awaiting discovery. The recently identified BRCA1-BCLAF1 complex mediating DNA damage-induced pre-mRNA splicing represents an emerging regulatory mechanism distinct from classical E3 ubiquitin ligase activity, suggesting BRCA1 possesses functional repertoires beyond those traditionally emphasized in the literature[50].

Mutations in BRCA1 confer extraordinarily high lifetime risks of breast cancer (>60%), ovarian cancer (39-58%), and elevated risks of additional cancers, establishing BRCA1 as one of the most penetrant cancer susceptibility genes in human genetics[44][47]. The specificity of cancer development in hormone-responsive tissues (breast, ovary) likely relates to the estrogen-responsive regulation of BRCA1 expression and metabolic attributes of these tissues[19][22][29]. Future research directions include comprehensive mapping of physiological BRCA1-BARD1 substrates, structural determination of BRCA1-protein complexes, characterization of tissue-specific BRCA1 functions, and therapeutic strategies targeting BRCA1-deficient cancers through synthetic lethality and targeted degradation approaches. Understanding BRCA1 biology remains central to comprehending hereditary cancer susceptibility and developing prevention and treatment strategies for carriers of BRCA1 mutations.

## Citations

1. https://pubmed.ncbi.nlm.nih.gov/10195418/
2. https://pmc.ncbi.nlm.nih.gov/articles/PMC3599463/
3. https://pubmed.ncbi.nlm.nih.gov/37797621/
4. https://www.uniprot.org/uniprotkb/P38398/entry
5. https://pmc.ncbi.nlm.nih.gov/articles/PMC4382744/
6. https://star-protocols.cell.com/protocols/3701
7. https://pubmed.ncbi.nlm.nih.gov/11925436/
8. https://pmc.ncbi.nlm.nih.gov/articles/PMC19361/
9. https://pmc.ncbi.nlm.nih.gov/articles/PMC133857/
10. https://www.pnas.org/doi/10.1073/pnas.94.22.12075
11. https://aacrjournals.org/cancerres/article/70/2/532/560818/Transcriptional-Autoregulation-by-BRCA1BRCA1
12. https://academic.oup.com/nar/article/34/5/1416/1145745
13. https://pmc.ncbi.nlm.nih.gov/articles/PMC2948912/
14. https://pmc.ncbi.nlm.nih.gov/articles/PMC2750839/
15. https://pmc.ncbi.nlm.nih.gov/articles/PMC140135/
16. https://febs.onlinelibrary.wiley.com/doi/10.1016/j.febslet.2011.05.005
17. https://pmc.ncbi.nlm.nih.gov/articles/PMC9481714/
18. https://pubs.acs.org/doi/abs/10.1021/bi970863d
19. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2022.844575/full
20. https://academic.oup.com/nar/article/53/17/gkaf848/8256625
21. https://pubmed.ncbi.nlm.nih.gov/17145961/
22. https://pmc.ncbi.nlm.nih.gov/articles/PMC3460552/
23. https://pmc.ncbi.nlm.nih.gov/articles/PMC10974778/
24. https://rupress.org/jcb/article/175/5/693/44619/BRCA1-foci-in-normal-S-phase-nuclei-are-linked-to
25. https://elifesciences.org/articles/30523
26. https://aacrjournals.org/cancerres/article/69/2_Supplement/606/552655/CtIP-a-BRCA1-binding-protein-is-a-transcriptional
27. https://pmc.ncbi.nlm.nih.gov/articles/PMC3141769/
28. https://pmc.ncbi.nlm.nih.gov/articles/PMC5683755/
29. https://pmc.ncbi.nlm.nih.gov/articles/PMC1462967/
30. https://www.oncotarget.com/article/11770/text/
31. https://pmc.ncbi.nlm.nih.gov/articles/PMC4442488/
32. https://aacrjournals.org/cancerres/article/66/3/1401/527497/Checkpoint-Kinase-2-Mediated-Phosphorylation-of
33. https://pmc.ncbi.nlm.nih.gov/articles/PMC16207/
34. https://pubs.acs.org/doi/pdf/10.1021/acs.biochem.5c00333
35. https://pmc.ncbi.nlm.nih.gov/articles/PMC9440284/
36. https://pmc.ncbi.nlm.nih.gov/articles/PMC5326557/
37. https://elifesciences.org/articles/80687
38. https://aacrjournals.org/cancerres/article/60/12/3299/506321/Role-for-ATM-in-DNA-Damage-induced-Phosphorylation
39. https://www.pnas.org/doi/10.1073/pnas.0836054100
40. https://pmc.ncbi.nlm.nih.gov/articles/PMC3982690/
41. https://pmc.ncbi.nlm.nih.gov/articles/PMC2150890/
42. https://en.wikipedia.org/wiki/Hereditary_breast%E2%80%93ovarian_cancer_syndrome
43. https://febs.onlinelibrary.wiley.com/doi/10.1111/febs.13150
44. https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2013.00182/full
45. https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet
46. https://pmc.ncbi.nlm.nih.gov/articles/PMC9643514/
47. https://pubmed.ncbi.nlm.nih.gov/17525340/
48. https://pmc.ncbi.nlm.nih.gov/articles/PMC4017265/
49. https://pubmed.ncbi.nlm.nih.gov/12354784/
50. https://www.science.org/doi/10.1126/science.1139476
51. https://aacrjournals.org/cancerres/article/79/9/2091/640683/BRCA1-No-Matter-How-You-Splice-ItBRCA1-Alternative
52. https://fanconi.org/clinical-care-guidelines/the-fanconi-anemia-dna-repair-pathway/
53. https://pubmed.ncbi.nlm.nih.gov/29440709/
54. https://pubmed.ncbi.nlm.nih.gov/14701743/
55. https://academic.oup.com/nar/article/45/22/12816/4588108
56. https://pmc.ncbi.nlm.nih.gov/articles/PMC2802901/
57. https://aacrjournals.org/cancerres/article/62/16/4588/509179/Phosphorylation-of-Serine-1387-in-Brca1-Is
58. https://pubmed.ncbi.nlm.nih.gov/24746700/